Latham & Watkins Advises on ADARx Pharmaceuticals’ Upsized US$446.3 Million Initial Public Offering

ADARx Pharmaceuticals, Inc., a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, has announced the pricing... The post Latham & Watkins Advises on ADARx Pharmaceuticals’ Upsized US$446.3 Million Initial Public Offering appeared first on Legal Desire Media and Insights .